Go Pro
→ Major Buy Alert Issued for August 31st (From TradeSmith) (Ad)tc pixel Free AMRX Stock Alerts

Amneal Pharmaceuticals (AMRX) Earnings Date, Estimates & Call Transcripts

Amneal Pharmaceuticals logo
$17.91 +0.01 (+0.06%)
As of 08/21/2026 04:00 PM Eastern
Compare

Amneal Pharmaceuticals Earnings Summary

Amneal Pharmaceuticals issued Q2 2026 earnings on July 30, 2026, reporting an EPS of $0.30, which topped analysts' consensus estimates of $0.24 by $0.06. Quarterly revenue was reported to be $796.20 million. With a trailing EPS of $0.49 and a P/E Ratio of 36.55, Amneal Pharmaceuticals' earnings are expected to grow 20.21% next year, from $0.94 to $1.13 per share.

Consensus EPS
(Jul. 30)
$0.24
Actual EPS
(Jul. 30)
$0.30 Beat By $0.06
Actual Revenue
(Jul. 30)
$796.20M

Q2 2026 Earnings Resources

Slide Deck

Amneal Pharmaceuticals' Q2 2026 Slide DeckFull Screen Slide Deck
Powered by Quartr
Get Amneal Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amneal Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

AMRX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

AMRX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Amneal Pharmaceuticals Analyst EPS Estimates

Current Year EPS Consensus Estimate
$0.94 EPS
Next Year EPS Consensus Estimate
$1.13 EPS

Amneal Pharmaceuticals Earnings History by Quarter

Export
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
7/30/2026Q2 2026$0.24$0.30+$0.06$0.18-$796.20M
5/7/2026Q1 2026 & M&A announcement-$0.27-$0.19-$722.52M
4/22/2026Q1 2026 & M&A announcement$0.15$0.26+$0.11$0.19$709.79M$723.00M
10/30/2025Q3 2025$0.12$0.17+$0.05$0.01-$784.51M
8/5/2025Q2 2025$0.17$0.23+$0.06$0.07-$724.51M
7/21/2025Q2 2025-$0.21---$695.42M
5/2/2025Q1 2025$0.14$0.19+$0.05$0.04$714.78M$695.42M
2/28/2025Q4 2024$0.15$0.12 -$0.03-$0.10$708.21M$730.52M

Amneal Pharmaceuticals Earnings - Frequently Asked Questions

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earning data on Thursday, July 30, 2026. Learn more on AMRX's earnings history.

Amneal Pharmaceuticals issued an update on its FY 2026 earnings guidance on Thursday, July, 30th. The company provided earnings per share guidance of 0.960-1.060 for the period, compared to the consensus earnings per share estimate of 0.970. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.1 billion.

In the previous quarter, Amneal Pharmaceuticals (NASDAQ:AMRX) reported $0.30 earnings per share (EPS) to beat the analysts' consensus estimate of $0.24 by $0.06. Learn more on analysts' earnings estimate vs. AMRX's actual earnings.

The conference call for Amneal Pharmaceuticals' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for Amneal Pharmaceuticals' latest earnings report can be read online.
Read Transcript

Amneal Pharmaceuticals' earnings report can be found in their filing with the SEC.
View SEC filing

Amneal Pharmaceuticals (NASDAQ:AMRX) has a recorded annual revenue of $3.02 billion.

Amneal Pharmaceuticals (NASDAQ:AMRX) has a recorded net income of $72.06 million. AMRX has generated $0.49 earnings per share over the last four quarters.

Amneal Pharmaceuticals (NASDAQ:AMRX) has a trailing price-to-earnings ratio of 36.55 and a forward price-to-earnings ratio of 19.05.

Amneal Pharmaceuticals' earnings are expected to grow from $0.94 per share to $1.13 per share in the next year, which is a 20.21% increase.

Related Companies
Earnings Tools

Earnings data for NASDAQ:AMRX is sourced from Fiscal.ai, with the most recent quarter reported on 7/30/2026. New results are added as companies report their earnings.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Your Free Report (Inside)
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
23,281 stocks. Only ONE survived.
One American energy producer just cleared a screen of 23281 stocks for elite operating profits, double-digit r...
Monument Traders Alliance | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
The world's #2 gold miner is running on fumes [it has to buy]
Barrick, the world's second-largest gold miner, produced 7.77 million ounces in 2010. This year, output is exp...
Golden Portfolio | Sponsoredtc pixel